A 38-year-old woman from Bangalore presents with a 2-month history of vaginal bleeding and lower abdominal pain. On examination, there is a 6 cm irregular pelvic mass. Pelvic ultrasound confirms a heterogeneous mass arising from the uterus with myometrial invasion. Serum β-hCG is 45,000 mIU/mL (normal <5) and serum LDH is 2,800 U/L (normal <480). A diagnosis of gestational trophoblastic neoplasia (GTN) is suspected. Which of the following tumor markers has the BEST prognostic significance and should be used to monitor treatment response in this patient?

Explanation

## Clinical Context The patient presents with features of gestational trophoblastic neoplasia (GTN), specifically invasive mole or choriocarcinoma: persistent vaginal bleeding, pelvic mass with myometrial invasion, markedly elevated β-hCG, and elevated LDH. These findings are pathognomonic for GTN. ## β-hCG as the Primary Tumor Marker for GTN **Key Point:** β-hCG (beta human chorionic gonadotropin) is the gold standard tumor marker for gestational trophoblastic neoplasia. It is: - Produced by trophoblastic tissue (both benign and malignant) - Highly sensitive and specific for GTN - Used for diagnosis, risk stratification, and monitoring treatment response - The most reliable indicator of disease burden and treatment efficacy **High-Yield:** β-hCG has a short half-life of 24–36 hours. A falling β-hCG level during treatment indicates response; a plateau or rising level suggests treatment failure or recurrence. Complete normalization of β-hCG is required for cure and must be maintained for 3 consecutive months before treatment is stopped. ## Prognostic Significance of β-hCG in GTN | β-hCG Level | Risk Category | Prognosis | |-------------|---------------|----------| | <1,000 mIU/mL | Low risk | Excellent (>95% cure with single-agent chemotherapy) | | 1,000–10,000 mIU/mL | Low risk | Excellent | | >10,000 mIU/mL | High risk | Requires multi-agent chemotherapy; lower cure rate | | >100,000 mIU/mL | Very high risk | Aggressive disease; highest mortality risk | **Clinical Pearl:** In this patient, β-hCG of 45,000 mIU/mL places her in the high-risk category. Combined with elevated LDH (indicating high tumor burden), this patient requires multi-agent chemotherapy (typically EMA-CO regimen). β-hCG should be monitored weekly during treatment; a >10% decline per week indicates good response. **Mnemonic for GTN Monitoring:** **BHCG** = **B**est marker, **H**igh sensitivity, **C**ure confirmation, **G**old standard. β-hCG is the only tumor marker needed for GTN management. ## Why Other Markers Are Inappropriate **Warning:** Do not confuse GTN with other malignancies: - AFP is elevated in germ cell tumors (yolk sac tumors, embryonal carcinomas) and hepatocellular carcinoma, NOT in GTN - CEA is non-specific and not used in GTN - CA-125 may be mildly elevated in GTN but is not specific or prognostically useful